Skip to main content

IMCD China strengthens its life science business with the acquisition of Daoqin

Written by Customer Service on . Posted in Mergers And Acquisitions.

Photo_IMCD China strengthens its lifescience business with the acquisition of Daoqin

(Left) Nicky Huang, Managing Director of IMCD China and IMCD Sanrise(Right) Jack Ning, General Manager of Daoqin
(Left) Nicky Huang, Managing Director of IMCD China and IMCD Sanrise(Right) Jack Ning, General Manager of Daoqin

ROTTERDAM, The Netherlands (13 December 2024) – IMCD N.V. (“IMCD” or “Company”), a global leading distribution partner and formulator of speciality chemicals and ingredients, today announces that IMCD has signed an agreement to acquire the business of the food and nutraceutical ingredient distributor: Daoqin Biological Technology (Shanghai) Co., Ltd., Longyu International Trade (Shanghai) Co., Ltd. and Long’en Biotechnology (Guangzhou) Co., Ltd. in China (jointly “Daoqin”). 

Established in 2011, Daoqin specialises in the distribution of functional nutrition, nutraceutical and food ingredients. Daoqin represents leading suppliers and offers, through its dedicated technical team and its laboratory, innovative solutions to its customers in the food, personal care and pharmaceutical industries. Daoqin is headquartered in Shanghai, China, and generated a revenue of approximately CNY 122 million (ca. EUR 16 million) in 2023 with 21 employees.  

“The addition of Daoqin marks another step in our journey to deepen our presence in the food and nutrition markets and broadens the scope of our life science business portfolio,” remarked Nicky Huang, Managing Director of IMCD China. “With the acquisition of Daoqin, we are very excited to welcome a very engaged and talented team and leverage our complementary portfolios and technical expertise to enhance our capabilities and offering in the local market,” concluded Huang.  

“The Daoqin team is excited to join IMCD, as we believe there are strong synergies between our businesses and capabilities,” said Jack Ning, General Manager of Daoqin. “By leveraging IMCD’s exceptional global network and resources, we look forward to bringing greater innovation and value to customers in the life sciences markets in China.” 

The closing of the transaction is subject to customary closing conditions and is expected to take place in the second quarter of 2025. 

Attached, the full press release in PDF format, the main visual and photo caption.

Attachments

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.